Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 May 2024 | Story Leonie Bolleurs | Photo Supplied
Inaugural
At the inaugural lecture of Prof Dirk Opperman were, from the left: Prof Opperman, Prof Vasu Reddy, Prof Koos Albertyn, Head of the Department of Microbiology and Biochemistry, and Prof Paul Oberholster, Dean of the Faculty of Natural and Agricultural Sciences.

Prof Dirk Opperman, a distinguished biochemist in the Department of Microbiology and Biochemistry, recently (21 May 2024) delivered his inaugural lecture on the Bloemfontein Campus of the University of the Free State (UFS).

The title of his lecture was: Exploring, Exploiting, and Evolving Life at the Atomic Level.

Prof Vasu Reddy, Deputy Vice-Chancellor: Research and Internationalisation at the UFS, welcomed guests, stating, "An inaugural lecture is a major milestone, celebrating a life’s work that culminates in the title of professor. It marks an important chapter in an academic career, with much more to be achieved in the journey of producing important knowledge.”

He believes that an event such as this highlights the university’s pride in the achievements of its academic staff and aligns with Vision 130. “The UFS is proud to host such lectures, as they are significant moments to reveal and showcase the value of excellence in our knowledge pool in research, teaching, and innovation. As a university, we strive to make a difference through groundbreaking work, particularly in addressing society's challenges,” said Prof Reddy, emphasising that this topic truly speaks to the university’s commitment to impactful work in the hard sciences.

Deciphering the unknown

The topic of the lecture captures the essence of Prof Opperman’s research. He explains that ‘exploring’ refers to the determination of the three-dimensional structures of proteins and enzymes. ‘Exploiting’ involves the use of these enzymes to convert substrates into products of value, and ‘evolving’ pertains to mutating the DNA to change the protein, giving it different functions, activities, selectivity, or specificities.

In his lecture, he remarked that if we know the structures of these proteins and enzymes, we can explore what to do with them and how to change them. According to him, there are the unknown knowns, the unknown unknowns, and the known unknowns. “We may know of specific activities and reactions by microorganisms, but we don’t know which enzyme is responsible; similarly, we can know the reactivity of an enzyme, but not necessarily their true physiological functions. I am trying to figure out all these unknowns,” he said.

In his lecture, he also raised the question of whether AI could replace experimental determination of protein structures. "No, not yet; it is only predictions," he believes, commenting that navigating the unknown unknowns is a dangerous place in science.

Establishing the field of structural biology

Prof Opperman, born and raised in the Free State, completed his undergraduate studies at the UFS. Later, in 2008, he obtained his PhD in Biochemistry from the same university. Following his doctoral studies, he conducted postdoctoral research on directed evolution under the guidance of Prof Manfred T Reetz at the Max Planck Institute for Coal Research in Germany, one of the world’s top institutions.

In 2010, he was appointed to the Department of Microbiology and Biochemistry at the UFS, where he has since established the field of structural biology, setting up the infrastructure essential for the advancement thereof. This includes equipment, techniques, and methods for determining the three-dimensional structure of proteins. “It is done using protein crystallisation and then X-ray diffraction,” he explains. Most of these X-ray diffraction experiments are then performed at particle accelerators called synchrotrons, such as Diamond Light Source (UK), which can produce intense X-rays.

His current research explores the interface of evolutionary and structure-function relationships of biocatalysts, with a particular focus on their application in green chemistry. Prof Opperman says that understanding both the structure and the function of an enzyme allows one to manipulate it to perform other functions.

Contributing to the broader goals of sustainable development

One of the projects he is working on highlights the potential for sustainable practices in waste management. Prof Opperman is currently part of a European Research Area Network Cofund partnership on Food Systems and Climate (FOSC), which focuses on developing biocatalysts for upcycling waste. An aspect of this work involves studying enzymes that degrade feathers, thereby converting feather waste into useful products such as fertiliser.

Regarding the contribution of his research to the broader goals of sustainable development and environmental protection, he says that enzymes are the base for biotechnology and the bioeconomy. “They can be sustainably produced, the reactions are environmentally friendly, and the resulting products can be classified as natural. There’s no need to use sources that are not sustainable to extract some of these molecules from,” he explains.

His significant contributions to the field are reflected in more than 50 authored and co-authored papers, some of which are published in prestigious journals such as Science, Nature Communications, and Angewandte Chemie. As an NRF B-rated researcher, his work has received funding from various local and international organisations, including industries such as Sasol and the Global Challenges Research Fund.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept